Identifying environmental contributions to autism: Provocative clues and false leads

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 10, Issue 4, 2004, Pages 292-302

  Lawler, Cindy P ^a   Croen, Lisa A ^b   Grether, Judith K ^c   Van De Water, Judy ^d  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b DIVISION OF RESEARCH   (United States)

^c CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism; Children's environmental health; Environmental response genes; Epidemiology; Epigenetics; Exposure assessment; Gene environment interaction; Genetic susceptibility; Immunology; Neurotoxicology; Prevalence; Surveillance; Toxicokinetics

Indexed keywords

AUTISM; BRAIN DEVELOPMENT; EARLY RESPONSE GENE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENETIC EPIGENESIS; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NEUROTOXICITY; PREVALENCE; PRIORITY JOURNAL; PROVOCATION; REVIEW; RISK ASSESSMENT; TOXICOKINETICS;

AUTISTIC DISORDER; AUTOANTIBODIES; BRAIN; ENVIRONMENTAL EXPOSURE; FEMALE; HAZARDOUS SUBSTANCES; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN;

EID: 13444279818     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrdd.20043     Document Type: Review

References (87)

1. Agency for Toxic Substances and Disease Registry. 2000. ATSDR Public Health Assessment: Brick Township Investigation. Atlanta, GA: Agency for Toxic Substances and Disease Registry.
2. Anderson GM, Home WC, Chatterjee D, et al. 1990. The hyperserotonemia of autism. Ann N Y Acad Sci 600:331-340; discussion 341-332.
3. Asperger H. 1944. Die "autistischen psychopathen" in kind esalter. Arc hive fur Psychiatrie nnd Nervenkrankheiten, 117, 76-136. Translated by Frith U, editor. Autism and Asperger Syndrome. 1991. Cambridge: Cambridge University, p 37-92
4. Asperger H. 1944. Die "autistischen psychopathen" in kind esalter. Arc hive fur Psychiatrie nnd Nervenkrankheiten, 117, 76-136. Translated by Frith U, editor. Autism and Asperger Syndrome. 1991. Cambridge: Cambridge University, p 37-92
5. Baird G, Charman T, Baron-Cohen S, et al. 2000. A screening instrument for autism at 18 months of age: A 6-year follow-up study. J Am Acad Child Adolesc Psychiatry 39:694-702.
6. Bernard S, Enayati A, Redwood L, et al. 2001. Autism: A novel form of mercury poisoning. Med Hypotheses 56:462-471.
7. Bertrand J, Mars A, Boyle C, et al. 2001. Prevalence of autism in a United States population: The Brick Township, New Jersey, investigation. Pediatrics 108:1155-1161.
8. Bigazzi PE. 1994. Autoimmunity and heavy metals. Lupus 3:449-453.
9. Burchiel SW, Luster MI. 2001. Signaling by environmental polycyclic aromatic hydrocarbons in human lymphocytes. Clin Immunol 98:2-10.
10. Chakrabarti S, Fombonne E. 2001. Pervasive developmental disorders in preschool children. JAMA 285:3093-3099.
11. Chen S, Golemboski K, Piepenbrink M, et al. 2004. Developmental immunotoxicity of lead in the rat: Influence of maternal diet. J Toxicol Environ Health A 67:495-511.
12. Committee on Developmental Toxicology, Board on Environmental Studies and Toxicology, National Research Council. 2000. Scientific Frontiers in Developmental Toxicology and Risk Assessment. Washington DC: National Academies Press.
13. Cook EH Jr., Lindgren V, Leventhal BL, et al. 1997. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am J Hum Genet 60:928-934.
14. Cook EH Jr, Perry BD, Dawson G, et al. 1993. Receptor inhibition by immunoglobulins: specific inhibition by autistic children, their relatives, and control subjects. J Autism Dev Disord 23:67-78.
15. Costa LG, Aschner M, Vitalone A, et al. 2004. Developmental neuropathology of environmental agents. Annu Rev Pharmacol Toxicol 44:87-110.
16. Courchesne E, Redcay E, Kennedy DP. 2004. The autistic brain: Birth through adulthood. Curr Opin Neurol 17:489-496.
17. Cox GF, Burger J, Up V, et al. 2002. Intracytoplasmic sperm injection may increase the risk of imprinting defects. Am J Hum Genet 71: 162-164.
18. Croen LA, Grether JK, Hoogstrate J, et al. 2002. The changing prevalence of autism in California. J Autism Dev Disord 32:207-15.
19. Dantzer R, Bluthe RM, Laye S, et al. 1998. Cytokines and sickness behavior. Ann N Y Acad Sci 840:586-590.
20. Davila DR, Romero DL, Burchiel SW. 1996. Human T cells are highly sensitive to suppression of mitogenesis by polycyclic aromatic hydrocarbons and this effect is differentially reversed by alpha-naphthoflavone. Toxicol Appl Pharmacol 139:333-341.
21. Donnelly SL, Wolpert CM, Menold MM, et al. 2000. Female with autistic disorder and monosomy X (Turner syndrome): Parent-of-origin effect of the X chromosome. Am J Med Genet 96:312-316.
22. Dunn AJ, Wang J, Ando T. 1999. Effects of cytokines on cerebral neurotransmission: Comparison with the effects of stress. Adv Exp Med Biol 461:117-127.
23. Dunzendorfer S, Kaser A, Meierhofer C, et al. 2000. Dendritic cell migration in different micropore filter assays. Immunol Lett 71:5-11.
24. EURODIAB ACE Study Group. 2000. Variation and trends in incidence of childhood diabetes in Europe. Lancet 355:873-876.
25. Ferguson JN, Young LJ, Hearn EF, et al. 2000. Social amnesia in mice lacking the oxytocin gene. Nat Genet 25:284-288.
26. Folstein SE, Rosen-Sheidley B. 2001. Genetics of autism: Complex aetiology for a heterogeneous disorder. Nat Rev Genet 2:943-955.
27. Fombonne E. 2002. Epidemiological trends in rates of autism. Mol Psychiatry 7 Suppl 2:S4-S6.
28. Gimpl G, Fahrenholz F. 2001. The oxytocin receptor system: Structure, function, and regulation. Physiol Rev 81:629-683.
29. Grether J, Croen L, Anderson M. 2004. Rates of autism for California live birth population, 1990-1995 (unpublished data from California Department of Developmental Services linked to Live Birth Vital Statistics).
30. Harpaz-Rotem I, Rosenheck RA. 2004. Changes in outpatient psychiatric diagnosis in privately insured children and adolescents from 1995 to 2000. Child Psychiatry Hum Dev 34:329-340.
31. Hornig M, Chian D, Lipkin WI. 2004. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol Psychiatry 9:833-835.
32. Hornig M, Lipkin WI. 2001. Infectious and immune factors in the pathogenesis of neurodevelopmental disorders: Epidemiology, hypotheses, and animal models. Ment Retard Dev Disabil Res Rev 7:200-210.
33. Hu H, Moller G, Abedi-Valugerdi M. 1997. Thiol compounds inhibit mercury-induced immunological and immunopathological alterations in susceptible mice. Clin Exp Immunol 107: 68-75.
34. Ilback NG, Sundberg J, Oskarsson A. 1991. Methyl mercury exposure via placenta and milk impairs natural killer (NK) cell function in newborn rats. Toxicol Lett 58:149-158.
35. Institute of Medicine. 2004. Immunization Safety Review: Vaccines and Autism. Board on Health Promotion and Disease Prevention.
36. Johnson WG. 2003. Teratogenic alleles and neuro-developmental disorders. Bioessays 25:464-477.
37. Jones MB, Palmour RM, Zwaigenbaum L, et al. 2004. Modifier effects in autism at the MAO-A and DBH loci. Am J Med Genet 126B:58-65.
38. Kanner L. 1943. Autistic disturbances of affective contact. Nervous Child 2:217-250.
39. Kelada SN, Eaton DL, Wang SS, et al. 2003. The role of genetic polymorphisms in environmental health. Environ Health Perspect 111: 1055-1064.
40. Kemper TL, Bauman ML. 2002. Neuropathology of infantile autism. Mol Psychiatry 7 Suppl 2:S12-S13.
41. Kozlovskaia GV, Kliushnik TP, Goriunova AV, et al. 2000. Nerve growth factor auto-antibodies in children with various forms of mental dysontogenesis and in schizophrenia high risk group. Zh Nevropatol Psikhiatr Im S S Korsakova 100:50-52.
42. Ladics GS, Kawabata TT, Munson AE, et al. 1992. Metabolism of benzo[a]pyrene by murine splenic cell types. Toxicol Appl Pharmacol 116:248-257.
43. Ladies GS, Kawabata TT, White KL Jr. 1991. Suppression of the in vitro humoral immune response of mouse splenocytes by 7,12-dimethylbenz[a]anthracene metabolites and inhibition of immunosuppression by alpha-naphthoflavone. Toxicol Appl Pharmacol 110:31-44.
44. Landrigan PJ, Kimmel CA, Correa A, et al. 2004. Children's health and the environment: Public health issues and challenges for risk assessment. Environ Health Perspect 112:257-265.
45. Larson SJ. 2002. Behavioral and motivational effects of immune-system activation. J Gen Psychol 129:401-414.
46. Licinio J, Kling MA, Hauser P. 1998. Cytokines and brain function: Relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 25:30-38.
47. London EA. 2000. The environment as an etiologic factor in autism: A new direction for research. Environ Health Perspect 108 Suppl 3:401-404.
48. McDougle CJ, Naylor ST, Cohen DJ, et al. 1996. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008.
49. Merali Z, Lacosta S, Anisman H. 1997. Effects of interleukin-1beta and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: A regional microdialysis study. Brain Res 761:225-235.
50. Miller TE, Golemboski KA, Ha RS, et al. 1998. Developmental exposure to lead causes persistent immunotoxicity in Fischer 344 rats. Toxicol Sci 42:129-135.
51. Mohankumar PS, Thyagarajan S, Quadri SK. 1991. Interleukin-1 stimulates the release of dopamine and dihydroxyphenylacetic acid from the hypothalamus in vivo. Life Sci 48:925-930.
52. Moore SJ, Turnpenny P, Quinn A, et al. 2000. A clinical study of 57 children with fetal anti-convulsant syndromes. J Med Genet 2000 37:489-497.
53. Muhle R, Trentacoste SV, Rapin I. 2004. The genetics of autism. Pediatrics 113:e472-e486.
54. Nelson KB, Bauman ML. 2003. Thimerosal and autism? Pediatrics 111:674-679.
55. Nelson KB, Grether JK, Croen LA, et al. 2001. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 49:597-606.
56. O'Fallon LR, Collman GW, Dearry A. 2000. The National Institute of Environmental Health Sciences' research program on children's environmental health. J Expo Anal Environ Epidemiol. 10(6 Pt 2):630-637.
57. Olden K, Wilson S. 2000. Environmental health and genomics: Visions and implications. Nat Rev Genet 1:149-153.
58. Osterling JA, Dawson G, Munson JA. 2002. Early recognition of 1-year-old infants with autism spectrum disorder versus mental retardation. Dev Psychopathol 14:239-251.
59. Pashenkov M, Teleshova N, Link H. 2003. Inflammation in the CNS: The role for dendritic cells. Brain Pathol 13:23-33.
60. Poser S, Stickel B, Krtsch U, et al. 1989. Increasing incidence of multiple sclerosis in South Lower Saxony, Germany. Neuroepidemiology 8:207-213.
61. Ransohoff RM, Kivisakk P, Kidd G. 2003. Three or more routes for leukocyte migration into the CNS. Nat Rev Immunol 3:569-581.
62. Rice D, Barone S Jr. 2000. Critical periods of vulnerability for the developing nervous system: Evidence from humans and animal models. Environ Health Perspect 108 Suppl 3:511-533.
63. Rodier PM. 2002. Converging evidence for brain stem injury in autism. Dev Psychopathol 14: 537-557.
64. Rodier PM. 2004. Environmental causes of CNS maldevelopment. Pediatrics 113(4 Suppl): 1076-1083.
65. Rodier PM, Ingram JL, Tisdale B, et al. 1996. Embryological origin for autism: Developmental anomalies of the cranial nerve motor nuclei. J Comp Neurol 370:247-261.
66. Rosati G, Aiello I, Mannu L, et al. 1988. Incidence of multiple sclerosis in the town of Sassari, Sardinia, 1965 to 1985: Evidence for increasing occurrence of the disease. Neurology 38: 384-388.
67. Salas VM, Burchiel SW. 1998. Apoptosis in Daudi human B cells in response to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol. Toxicol Appl Pharmacol 151:367-376.
68. Schieve LA, Rasmussen SA, Buck GM, et al. 2004. Are children born after assisted reproductive technology at increased risk for adverse health outcomes? Obstet Gynecol 103:1154-1163.
69. Shintani F, Kanba S, Nakaki T, et al. 1993. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci 13:3574-3581.
70. Singh VK, Singh EA, Warren RP. 1997a. Hyperserotoninemia and serotonin receptor antibodies in children with autism but not mental retardation. Biol Psychiatry 41:753-755.
71. Singh VK, Warren R, Averett R, et al. 1997b. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatric Neurol 17:88-90.
72. Singh VK, Warren RP, Odell JD, et al. 1993. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immun 7:97-103.
73. Strömland K, Nordin V, Miller M, et al. 1994. Autism in thalidomide embryopathy: A population study. Dev Med Child Neurol 36: 351-356.
74. Suk WA, Murray K, Avakian MD. 2003. Environmental hazards to children's health in the modern world. Mutat Res 544:235-242.
75. United States Environmental Protection Agency. 2003. America's children and the environment: Measures of contaminants, body burden and illnesses, EPA 240R03001.
76. Upton MN, McConnachie A, McSharry C, et al. 2000. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: The Midspan family study surveys of parents and offspring. Br Med J 321:88-92.
77. van Gent T, Heijnen CJ, Treffers PD. 1997. Autism and the immune system. J Child Psychol Psychiatry Allied Discip 38:337-349.
78. Wakefield AJ, Murch SH, Anthony A, et al. 1998. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998 351:637-641.
79. Ward EC, Murray MJ, Lauer LD, et al. 1984. Immunosuppression following 7,12-dimethylbenz[a]anthracene exposure in B6C3F1 mice. I. Effects on humoral immunity and host resistance. Toxicol Appl Pharmacol 75: 299-308.
80. Waterland RA, Jirtle RL. 2004. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition 20:63-68.
81. Williams HC. 1992. Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol 17: 385-391.
82. Wilson CJ, Finch CE, Cohen HJ. 2002. Cytokines and cognition: The case for a head-to-toe inflammatory paradigm. Geriatric Biosci 50: 2041-2056.
83. Wilson SH, Olden K. 2004. The environmental genome project: Phase I and beyond. Mol Interv 4:147-156.
84. Wirleitner B, Neurauter G, Schrocksnadel K, et al. 2003. Interferon-gamma-induced conversion of tryptophan: Immunologic and neuropsychiatric aspects. Curr Med Chem 10:1581-1591.
85. Woolcock AJ, Peat JK. 1997. Evidence for the increase in asthma worldwide. Ciba Found Symp 206:122-134.
86. Yeargin-Allsopp M, Rice C, Karapurkar T, et al. 2003. Prevalence of autism in a US metropolitan area. JAMA 289:49-55.
87. Young LJ, Pitkow LJ, Ferguson JN. 2002. Neuropeptides and social behavior: Animal models relevant to autism. Mol Psychiatry 7 Suppl 2:S38-S39.